The U.K. Competition Appeal Tribunal has decided not to enforce a more stringent statute of limitations that would have dismissed government allegations against Lundbeck Ltd. and certain generic drug manufacturers. The claims involve accusations of anticompetitive agreements to defer the release of generic alternatives to a widely used antidepressant. As a result, the case will now proceed, allowing the authorities to continue their investigation into the purportedly anticompetitive practices.
Further details can be found in the original reporting by Law360.